Advertisement
Heart, Lung and Circulation
Editorial| Volume 20, ISSUE 4, P211-213, April 2011

Metabolic syndrome—Is the whole really greater than the sum of the parts?

      The metabolic syndrome (MetS), comprising the cardiovascular risk factors of obesity, hypertension, diabetes, elevated plasma triglycerides and low high-density cholesterol, is now well-recognised as being associated with increased risk of cardiovascular disease. The question arises, however, of whether or not the constellation of factors, defined as the MetS confers a specific increase in cardiovascular risk, beyond that conferred by the individual risk factors themselves. This question is not merely academic, as if the MetS did confer additional risk, then we may well wish to be more aggressive about treatment of individual factors in patients with the MetS, and of course wish to identify the specific risk-factor interactions responsible for the incremental risk associated with MetS. It is this question, which is addressed by Simons et al. in their paper in the current issue of the journal [
      • Simons L.A.
      • Simons J.
      • Friedlander Y.
      • McCallum J.
      Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo Study.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simons L.A.
        • Simons J.
        • Friedlander Y.
        • McCallum J.
        Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo Study.
        Heart Lung Circulation. 2011; 20: 214-219
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • Donato K.A.
        • Eckel R.H.
        • Frankli B.A.
        • et al.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
        Circulation. 2005; 112: 2735-2752
        • Dekker J.M.
        • Girman C.
        • Rhodes T.
        • Nijpels G.
        • Stehouwer C.D.A.
        • Bouter L.M.
        • et al.
        Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.
        Circulation. 2005; 112: 666-673
        • Schillaci G.
        • Pirro M.
        • Vaudo G.
        • Gemelli F.
        • Marchesi S.
        • Porcellati C.
        • et al.
        Prognostic value of the metabolic syndrome in essential hypertension.
        J Am Coll Cardiol. 2004; 43: 1817-1822
        • Malik S.
        • Wong N.D.
        • Franklin S.S.
        • Kamath T.V.
        • L’Italien G.J.
        • Pio J.R.
        • et al.
        Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.
        Circulation. 2004; 110: 1245-1250
        • Wannamethee S.G.
        • Shaper A.G.
        • Lennon L.
        • Morris R.W.
        Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke and Type 2 diabetes mellitus.
        Arch Intern Med. 2005; 165: 2644-2650
        • Stern M.P.
        • Williams K.
        • Gonzalez-Villalpando C.
        • Hunt K.J.
        • Haffner S.M.
        Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?.
        Diabetes Care. 2004; 27: 2676-2681